Drug Trial Radar · NCT07593079
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Dec 14, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Society of Nuclear Medicine and Molecular Imaging
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low levels of PSA. Adult patients with biochemically recurrent prostate cancer (BCR PCa) who have a PSA of less than 1.0 ng/mL and who have undergone complete prostatectomy and/or will be undergoing radiotherapy, in combination with standard of care bicalutamide, will be recruited to this study. Patients will be randomized in a 1:1 ratio into Group A (baseline PSMA PET/CT only with bicalutamide standard of care) or Group B (baseline PSMA PET/CT and an additional PSMA PET/CT after 2 weeks of bicalutamide).
Conditions
- Prostate Cancer
- Recurrent Prostate Cancer
- Metastatic Prostate Cancer
- Prostate Cancer Recurrent
- Prostate Cancer Metastatic
Interventions
BicalutamideDrug
Bicalutamide is a non-steroidal androgen receptor inhibitor administered as a once a day pill taken orally. This is given as standard of care.
Prostate-specific membrane antigen Positron Emission Tomography-Computed TomographyDevice
Patients will undergo prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) imaging. Each PSMA PET-CT session will consist of 5 minutes of dynamic imaging conducted via the Biograph Vision Quadra PET-CT, a whole-body PET-CT scanner.
18F-rhPSMA-7.3Drug
Radioactive diagnostic agent for intravenous use.
PROSTestDiagnostic test
PROSTest is a novel, blood-based qPCR assay that assesses gene expression to diagnose PCa and predict patient outcomes to different treatments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Group B only: Lesion detection rates between PET1 and PET2.Time frame: Baseline and 14 days after start of bicalutamide treatment (total estimated time 14 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.